Philips Respironics DOJ Settlement: €288 Million Deal to End CPAP Recall Criminal and Civil Probes

The Philips Respironics DOJ settlement is an agreement in principle, announced by Philips on November 3, 2026, to resolve the US Justice Department's criminal and civil investigations into the 2021 recall of millions of CPAP, BiPAP and ventilator devices, and Philips has set aside €288 million (about $322 million) to pay for it in the first quarter of 2027. The deal is not yet signed, its terms and any admissions are undisclosed, and it pays the federal government rather than the patients who used the recalled machines.

That last point is the one most likely to be misunderstood. Headlines describing a "Philips CPAP settlement" will send recall-affected users looking for a claim form. There is none. The personal injury, medical monitoring and economic loss money was negotiated separately in MDL No. 3014 in 2023 and 2024. What changed this week is that the last major federal enforcement exposure arising from the recall now has a price, and the remaining open fronts are a state attorneys general investigation, the opt-out cases still pending in the MDL, and whatever the final DOJ paperwork says.

What Philips agreed to with the Justice Department

Philips disclosed the agreement with its third-quarter 2026 results. In the company's words, Philips Respironics "reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall." The company recorded a provision of €288 million in the quarter. Its 2026 outlook assumes "payment of the US DOJ settlement in the first quarter of 2027, which is subject to finalization of the relevant documentation."

Chief executive Roy Jakobs called the agreement an "important step" in resolving the consequences of the recall. Asked about substance, including whether the agreement contains an admission of wrongdoing, he declined: "We cannot provide details qualitatively at this point in time." Negotiations over the final documents are continuing.

The "previously disclosed" investigations trace back to April 8, 2022, when the Justice Department served subpoenas on Philips and its subsidiaries seeking information about the events leading up to the recall. In parallel, DOJ pursued a civil injunction under the Federal Food, Drug, and Cosmetic Act that produced the 2024 consent decree discussed below. The agreement in principle is the first public sign that the criminal side of the inquiry, which had been open for roughly four and a half years, will end in a negotiated resolution rather than a contested indictment.

The financial effect was visible in the quarter. Philips reported net income of €28 million, down from €187 million a year earlier, with the provision accounting for most of the drop. Operationally the company did well: comparable sales rose 3%, comparable order intake rose 8%, and the adjusted EBITA margin improved 70 basis points to 13.0% on group sales of about €4.4 billion. Philips reiterated its 2026 guidance of 3% to 4.5% comparable sales growth, a 13.5% to 14.0% adjusted EBITA margin, and free cash flow of €1.5 billion to €1.7 billion.

How much is Philips paying in the DOJ settlement?

Philips is paying €288 million, which most US outlets have converted to about $322 million, under the Philips Respironics DOJ settlement. That is the amount of the provision booked in the third quarter of 2026; Philips has not said whether the final number could move, and the figure covers both the criminal and civil investigations combined.

Two cautions about the number. First, it is a reserve recorded under accounting rules, not a published settlement agreement, so the eventual DOJ press release could allocate it among a criminal fine, forfeiture, civil penalties or a False Claims Act-style recovery in ways that are not yet visible. Second, some coverage has reported "$288 million" by carrying over the euro figure; the provision is denominated in euros, and the dollar equivalent will float with the exchange rate until payment.

For scale, the DOJ amount is well under half of what Philips has already committed to private plaintiffs. The personal injury program alone was $1.075 billion, and the economic loss class settlement started at a $479 million prefund.

What does the Philips Respironics DOJ settlement resolve?

The Philips Respironics DOJ settlement resolves, according to Philips, "the previously disclosed criminal and civil investigations related to the Respironics recall." Nothing more specific has been released: not the statutes, not the entity or entities that would be charged or released, and not whether any individual employees are covered.

The recall at the center of those investigations began on June 14, 2021, when Philips Respironics announced that the polyester-based polyurethane (PE-PUR) sound-abatement foam inside certain DreamStation CPAP and BiPAP machines and some ventilators could break down, with particles and chemicals potentially inhaled or ingested by users. Philips puts the worldwide total at about 15 million devices. The US economic loss class settlement covered 10.8 million CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021. (Some outlets cite "5.5 million machines and 17 million masks"; those figures count different things and do not displace the company and court-approved totals.)

Two strands of reporting shaped the government's interest. The FDA has received more than 116,000 medical device reports tied to the foam since April 2021, including 561 reports of death, though the agency stresses that such reports are unverified and do not establish causation. And a 2023 ProPublica and Pittsburgh Post-Gazette investigation reported that Philips had received more than 3,700 complaints about foam degradation over 11 years before it launched the recall. On October 10, 2023, Senator Richard Blumenthal wrote to FDA Commissioner Robert Califf and Attorney General Merrick Garland urging both agencies to "hold the company accountable for past violations."

What the agreement does not resolve is just as important: the state attorneys general investigation, any remaining private lawsuits, and Philips' obligations under the existing consent decree all continue on their own tracks.

Is the Philips DOJ settlement final?

No. Philips describes it as an agreement in principle that is "subject to finalization of the relevant documentation," with payment expected in the first quarter of 2027.

If the resolution includes a criminal plea, it will also need a federal judge. Under Federal Rule of Criminal Procedure 11, a court must accept a guilty plea and may accept or reject a plea agreement that binds the sentence. A deferred prosecution agreement is filed with a criminal information and requires the court to approve the speedy-trial exclusion, while a non-prosecution agreement is a letter contract that never reaches a docket. Civil components are typically documented in a separate settlement agreement and, if any claim was pleaded, a stipulated dismissal. Until DOJ announces the final package, every description of its structure, including this one, is inference from the company's disclosure.

Did Philips admit wrongdoing?

Philips has not said, and Jakobs declined to answer when asked directly. The 2024 consent decree expressly was not an admission of the allegations in the government's complaint, and the 2024 personal injury settlement was reached without any admission of liability.

The structure of the criminal piece will determine how much an admission matters. The FDCA, at 21 U.S.C. § 333(a)(1), makes introducing an adulterated or misbranded device into interstate commerce a strict-liability misdemeanor, and under United States v. Park (1975) a "responsible corporate officer" can be convicted without proof of personal intent. Section 333(a)(2) raises the offense to a felony when committed with intent to defraud or mislead. A corporate guilty plea of either kind would carry a factual basis that the company accepts in open court. A deferred or non-prosecution agreement usually attaches an agreed statement of facts and bars the company from publicly contradicting it, but produces no conviction.

For civil litigants the distinction has evidentiary consequences. Federal Rule of Evidence 803(22) admits a judgment of conviction for a crime punishable by more than a year to prove facts essential to the judgment, which reaches a felony plea but not a misdemeanor. Statements of fact in a DPA or plea agreement can still be offered as a party's own admissions, subject to the ordinary relevance and prejudice fights. That is why plaintiffs' firms holding opt-out cases will read the final paperwork closely.

Every Philips Respironics recall resolution so far

Date	Matter	Forum	Amount	Status
June 14, 2021	Voluntary recall of foam-containing sleep and respiratory devices	FDA (Class I recall)	Remediation cost borne by Philips	Remediation largely complete
April 8, 2022	DOJ subpoenas on events leading to recall	DOJ	n/a	Resolved in principle Nov. 3, 2026
Sept. 2022	False Claims Act settlement over kickbacks to DME suppliers (unrelated to foam)	D.S.C., No. 2:19-cv-02913	Over $24 million	Final; five-year Corporate Integrity Agreement
Sept. 2023 / April 25, 2024	Economic loss class settlement	W.D. Pa., MDL No. 3014 (Judge Joy Flowers Conti)	At least $479 million	Final approval April 25, 2024
April 9, 2024	Consent decree of permanent injunction under the FDCA	W.D. Pa.	Compliance and remediation obligations	In force
April 29, 2024	Personal injury settlement	MDL No. 3014 (private program)	$1.075 billion	In final payout phase, per trackers
April 29, 2024 / Dec. 5, 2024	Medical monitoring class settlement	MDL No. 3014	$25 million	Final judgment Dec. 5, 2024
2024 onward	State attorneys general trade-practices investigation	41 US states and territories	Undisclosed	Open; excluded from outlook
Nov. 3, 2026	DOJ criminal and civil investigations	DOJ	€288 million (about $322 million)	Agreement in principle; payment expected Q1 2027

The 2022 False Claims Act matter is worth flagging because it is sometimes conflated with the recall. In that case Philips RS North America, formerly Respironics, agreed to pay more than $24 million ($22.62 million to the United States and $2.13 million to state Medicaid programs) to resolve allegations that it gave durable medical equipment suppliers illegal inducements, including free physician-prescribing data. Former employee Jeremy Orling filed the qui tam and was slated to receive about $4.3 million. The settlement came with a five-year Corporate Integrity Agreement with the HHS Office of Inspector General, which means Respironics was already under an integrity monitor when the recall investigations were active.

Does the Philips Respironics DOJ settlement pay CPAP users?

No. The Philips Respironics DOJ settlement pays the US government, and no portion has been announced for recall-affected patients, nor is there any claims process attached to it.

There is one narrow route by which a criminal resolution can reach individuals. If the final package includes a federal plea or criminal information, the Crime Victims' Rights Act, 18 U.S.C. § 3771, gives anyone "directly and proximately harmed" by the charged offense the right to be reasonably heard at any plea or sentencing hearing and the right to "full and timely restitution as provided in law." In complex corporate cases, the restitution statute lets courts decline restitution where fashioning it would unduly complicate or prolong sentencing (18 U.S.C. § 3663A(c)(3)), and the existence of large private settlements is commonly cited as a reason restitution is unnecessary. Users should not expect DOJ money to arrive as compensation; the real compensation vehicles were the MDL settlements.

Those vehicles are largely spent. The $1.075 billion personal injury program and the $25 million medical monitoring settlement were structured around claimants who had filed or registered claims under the program's terms, and trackers report the personal injury fund has been in its final distribution phase in 2026. The economic loss class, which reimbursed device purchase and replacement costs, received final approval in April 2024.

Where MDL 3014 stands, and can new claims still be filed?

MDL No. 3014, In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation, remains pending before Judge Joy Flowers Conti in the Western District of Pennsylvania. Trackers citing Judicial Panel on Multidistrict Litigation statistics show roughly 620 pending actions in fall 2026: 624 in the August report and 623 in October. Those are largely plaintiffs who did not take the 2024 settlement, plus some state court cases outside the MDL.

Can a new Philips CPAP lawsuit still be filed? Technically anyone can file, but most new claims will face serious statute of limitations defenses. The recall was announced in June 2021 and heavily publicized, and personal injury limitations periods in most states run two or three years. A claimant who was diagnosed recently, or who can show under their state's discovery rule that they could not reasonably have connected an illness to the device earlier, may have an argument; a claimant who knew of the recall and their condition in 2021 generally will not. Wrongful death claims follow their own state-specific clocks, which usually start at death. The DOJ settlement does not revive or toll any of those periods.

For the opt-out docket, the bigger question is whether the eventual DOJ documents supply admissions or agreed facts that change trial or settlement value, especially on notice, the timing of complaint review, and design or testing choices for the PE-PUR foam. That is the evidentiary payoff plaintiffs have waited for since the April 2022 subpoenas.

What investigations are still open against Philips?

The largest open matter is a multistate investigation by state attorneys general into trade practices related to the recalled products. Philips' filings say the inquiry was initiated in 2024 and that the company "continued to actively engage with the state AGs for 41 US states and territories." Philips' 2026 outlook expressly excludes it, along with "other ongoing Philips Respironics-related proceedings."

State consumer-protection statutes typically authorize civil penalties per violation, injunctive relief and restitution for state residents, so a multistate resolution, unlike the DOJ deal, could include a consumer payment or a restitution component. No amount has been reported.

Beyond the attorneys general, Philips continues to carry the consent decree's compliance obligations, and the remaining MDL opt-out cases. The DOJ agreement takes the federal criminal risk, the most open-ended exposure, off the table once signed.

Can Philips sell CPAP machines in the US again?

Mostly no. Under the April 9, 2024 consent decree, Philips cannot sell new CPAP or BiPAP sleep therapy devices or other respiratory care devices from its Pennsylvania facilities in Murrysville and New Kensington, or restart production at its Carlsbad, California plant, until it satisfies the decree's requirements.

The decree, entered by the US District Court for the Western District of Pennsylvania against Philips RS North America LLC, Respironics California LLC, Philips Holding USA Inc., Roy Jakobs and other individual defendants, followed a DOJ complaint alleging that the devices were adulterated because they were not made in conformity with current good manufacturing practice requirements. It requires Philips to complete remediation of recalled devices (a new device, a reworked device, or a partial refund), retain independent experts to review its testing and facilities, and meet FDA-approved conditions before resuming production. Philips may still service devices already in use and sell accessories, consumables and replacement parts.

There has been one narrow exception. In March 2026 Philips made DreamStation BiPAP AVAPS devices available in the United States as new setups for a small group of pediatric obstructive sleep apnea patients over age 7 who weigh 40 to 66 pounds, according to trade press. No timetable for a general return of Philips CPAP machines to the US market has been announced, and the DOJ agreement in principle does not by itself lift any part of the decree.

What it means for claimants' counsel, defendants, regulators and funders

For plaintiffs' firms with opt-out cases. The final DOJ documents are the most important new evidence source in MDL 3014 since fact discovery. Counsel should be ready to move quickly on any statement of facts, plea colloquy or charging document, and to argue admissibility under the party-admission rule and, for a felony conviction, Rule 803(22). Settlement value for strong opt-out cases may rise if the facts are damaging; it may not if the resolution is a non-prosecution agreement with a thin statement.

For firms fielding new inquiries. Expect a spike in calls from consumers who read "Philips settlement" and assume a new fund exists. Intake scripts should explain that the DOJ money goes to the government, that the 2024 programs were for existing claimants, and that limitations will bar most new claims. The duty to screen limitations at intake is acute here because the recall date is fixed and public.

For device-maker defendants and their counsel. The Philips sequence (recall, subpoenas within ten months, FDCA consent decree with an individual chief executive as a named defendant, then a combined criminal and civil resolution more than five years after the recall) is a template for how the Justice Department now approaches serious device recalls. Companies negotiating private mass tort settlements while a criminal investigation is open should assume that admissions in the later criminal resolution will be offered against them by every plaintiff who opted out.

For state attorneys general. Federal resolution typically sets an anchor. The 41-jurisdiction group now knows the size of the federal number and can negotiate for consumer restitution, which DOJ is unlikely to provide.

For litigation funders. Funders with positions in opt-out Philips cases should treat the final DOJ paperwork as a valuation event. A resolution with a detailed agreed statement of facts strengthens liability; a bare payment with no admission leaves the cases where they were. Either way, the reduced overall exposure may make Philips more willing to clear the remaining MDL inventory.

FAQ

How much is Philips paying in the DOJ settlement over the CPAP recall?

Philips has set aside €288 million, about $322 million, to resolve the Justice Department's criminal and civil investigations into the Respironics recall, with payment expected in the first quarter of 2027.

Is the Philips DOJ settlement final?

No. It is an agreement in principle announced November 3, 2026, and it remains subject to finalization of the settlement documents; any criminal plea component would also need court approval.

Does the Philips DOJ settlement pay CPAP users?

No. The money goes to the federal government. Patients were compensated through the separate $1.075 billion personal injury settlement, $25 million medical monitoring settlement, and $479 million-plus economic loss class settlement in MDL No. 3014.

Did Philips admit wrongdoing?

Philips has not disclosed whether the agreement includes any admission, and CEO Roy Jakobs declined to give details. The earlier consent decree and personal injury settlement contained no admission of liability.

What other investigations does Philips still face over the CPAP recall?

A trade-practices investigation by state attorneys general covering 41 US states and territories remains open and is excluded from Philips' 2026 financial outlook, along with other Respironics-related proceedings.

Can I still file a Philips CPAP lawsuit?

New claims are possible only where state statutes of limitations allow; because the recall was announced in June 2021, most two- and three-year limitations periods have run, unless a later diagnosis or the discovery rule extends them.